アトピー性皮膚炎治療薬の世界市場：薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

世界のアトピー性皮膚炎治療薬の市場規模は、2025年～2032年の予測期間中に8.17％のCAGRで拡大し、2024年の182億7,000万米ドルから2032年には342億5,000万米ドルに成長すると予測されています。同市場の成長は、世界中の様々な地域でアトピー性皮膚炎の症例が増加していること、アトピー性皮膚炎に対する認識が高まっていること、様々な規制機関からの製品承認が増加していることが背景にあります。全米湿疹協会の推計によると、全世界の子供の約10％から20％、成人の2％から10％がアトピー性皮膚炎としても知られる湿疹に悩まされています。アトピー性皮膚炎の症例が増加している様々な要因には、汚染レベルの上昇、都市型ライフスタイルの増加、環境の変化などがあります。

副腎皮質ステロイド、カルシニューリン阻害剤、PDE4阻害剤、生物学的製剤などが、炎症を抑え、アトピー性皮膚炎を管理するために一般的に処方されています。副腎皮質ステロイドは再燃時に使用され、カルシニューリン阻害薬は長期維持のためのステロイド温存薬として機能します。重症例にはコルチコステロイド外用薬による湿潤ラップ療法が推奨されます。この疾患は、ライフスタイルの影響や環境因子のために、農村部に比べて工業地帯や都市部でより多くみられる傾向があります。

当レポートでは、世界のアトピー性皮膚炎治療薬市場について調査し、市場の概要とともに、薬剤クラス別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のアトピー性皮膚炎治療薬市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
• 2024年市場マップ分析
  • 薬剤クラス別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 北米のアトピー性皮膚炎治療薬市場の見通し、2018年～2032年

第6章 欧州のアトピー性皮膚炎治療薬市場の見通し、2018年～2032年

第7章 アジア太平洋のアトピー性皮膚炎治療薬市場の見通し、2018年～2032年

第8章 南米のアトピー性皮膚炎治療薬市場の見通し、2018年～2032年

第9章 中東・アフリカのアトピー性皮膚炎治療薬市場の見通し、2018年～2032年

第10章 アトピー性皮膚炎の世界的疫学

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

• 市場の促進要因
• 市場の課題

第17章 市場動向と発展

第18章 臨床試験の概要

第19章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Pfizer Inc.
  • Sanofi SA
  • AbbVie Inc.
  • Galderma Laboratories, L.P.
  • Novartis AG
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • LEO Pharma Inc.
  • Otsuka Pharmaceutical Co., Ltd
  • Incyte Corporation

第20章 戦略的提言

第21章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 3. Global Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 4. Global Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. Global Atopic Dermatitis Drugs Market Share (%), By Region, 2018-2032F
• Figure 6. North America Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 8. North America Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 9. North America Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America Atopic Dermatitis Drugs Market Share (%), By Country, 2018-2032F
• Figure 11. United States Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 13. United States Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 14. United States Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 17. Canada Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 18. Canada Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 21. Mexico Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 22. Mexico Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 25. Europe Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 26. Europe Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe Atopic Dermatitis Drugs Market Share (%), By Country, 2018-2032F
• Figure 28. Germany Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 30. Germany Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 31. Germany Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 34. France Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 35. France Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 38. Italy Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 39. Italy Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 42. United Kingdom Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 43. United Kingdom Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 46. Russia Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 47. Russia Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 50. Netherlands Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 51. Netherlands Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 54. Spain Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 55. Spain Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 58. Turkey Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 59. Turkey Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 62. Poland Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 63. Poland Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. Asia-Pacific Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Asia-Pacific Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 66. Asia-Pacific Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 67. Asia-Pacific Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. Asia-Pacific Atopic Dermatitis Drugs Market Share (%), By Country, 2018-2032F
• Figure 69. India Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 70. India Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 71. India Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 72. India Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. China Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 74. China Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 75. China Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 76. China Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Japan Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Japan Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 79. Japan Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 80. Japan Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Australia Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 82. Australia Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 83. Australia Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 84. Australia Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 85. Vietnam Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Vietnam Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 87. Vietnam Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 88. Vietnam Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 89. South Korea Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 90. South Korea Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 91. South Korea Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 92. South Korea Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 93. Indonesia Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 94. Indonesia Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 95. Indonesia Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 96. Indonesia Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 97. Philippines Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 98. Philippines Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 99. Philippines Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 100. Philippines Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 101. South America Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 102. South America Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 103. South America Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 104. South America Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 105. South America Atopic Dermatitis Drugs Market Share (%), By Country, 2018-2032F
• Figure 106. Brazil Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Brazil Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 108. Brazil Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 109. Brazil Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Argentina Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Argentina Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 112. Argentina Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 113. Argentina Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 116. Middle East & Africa Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 117. Middle East & Africa Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa Atopic Dermatitis Drugs Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 121. Saudi Arabia Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 122. Saudi Arabia Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 125. UAE Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 126. UAE Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa Atopic Dermatitis Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa Atopic Dermatitis Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 129. South Africa Atopic Dermatitis Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 130. South Africa Atopic Dermatitis Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global atopic dermatitis drugs market is projected to witness a CAGR of 8.17% during the forecast period 2025-2032, growing from USD 18.27 billion in 2024 to USD 34.25 billion in 2032. The market's growth is augmented by the rising cases of atopic dermatitis in different regions across the globe, growing awareness about the condition, and increasing product approvals from different regulatory bodies. According to the estimates of the National Eczema Association, approximately 10% to 20% of children and 2% to 10% of adults across the globe suffer from eczema, also known as atopic dermatitis. The different factors attributed to the increasing cases of atopic dermatitis include rising pollution levels, increasing adoption of urban lifestyle, and environmental changes.

Corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics, among others are commonly prescribed to reduce inflammation and manage atopic dermatitis. Corticosteroids are used during flare-ups, while calcineurin inhibitors serve as steroid-sparing agents for long-term maintenance. Wet-wrap therapy with topical corticosteroids is recommended for severe cases. The condition tends to be more common in industrialized and urban locations as compared to rural areas because of lifestyle influences and environmental factors.

Rising Research Activities Support Market Growth

Pharmaceutical companies are increasingly investing in research and development to address the unmet needs of the patient population in managing atopic dermatitis. Collaborations between pharmaceutical companies, dermatological researchers, and contract research organizations are fostering shared expertise, risk mitigation, and accelerated product development. Additionally, unconventional approaches such as microbiome-targeted therapies and monoclonal antibodies are gaining traction, offering personalized care solutions for the patient population. Due to these increasing research and development efforts, pharmaceutical companies across the globe are receiving regulatory approvals for their products. For instance, in March 2024, Maruho Co., Ltd., received approval from Japan's Ministry of Health, Labour and Welfare for Mitchga subcutaneous injection 30 mg vials. Mitchga, a humanized anti-human IL-31 receptor A monoclonal antibody, works by blocking IL-31, a key mediator of itching and inflammation in various skin conditions. The approval is based on Phase III and Phase II/III clinical studies demonstrating Mitchga's efficacy and safety in Japanese patients with atopic dermatitis and prurigo nodularis who had inadequate responses to conventional therapies.

Increasing Accessibility Boosts Market Expansion

The rising accessibility of atopic dermatitis drugs is driving market's growth by improving treatment availability and affordability for the patient population. Different distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, ensure that patients can access medications in a convenient manner. Meanwhile, the rise of telemedicine and patient-centric care models further enhances drug accessibility. These services enable consultations and prescriptions for atopic dermatitis treatments without requiring physical visits, especially beneficial for patients in remote locations. Moreover, pharmaceutical companies are focusing on developing cost-effective alternatives and expanding their product portfolios across the globe. The introduction of generic drugs and biosimilars provides affordable options for patients.

Biologics Account for Significant Share of the Market

The growth of the segment can be attributed to the increasing product approvals, high efficacy, and the significant advantages offered by biologics over conventional topical treatment options. They target the inflammatory mechanisms that are responsible for fostering the condition and not just aid in managing the symptoms. Thus, leading pharmaceutical companies across the globe are focusing on launching new biologics. For instance, in December 2024, Galderma SA received approval from the United States Food and Drug Administration (US FDA) for Nemluvio (Nemolizumab) for patients suffering from severe to moderate atopic dermatitis. Nemluvio's innovative mechanism of action and clinical trial success highlights its potential to significantly improve patient outcomes and support the management of such challenging skin conditions. Such approvals are expected to provide lucrative growth opportunities for the market and support the segment's expansion.

North America Holds Major Market Share

The market's growth in North America can be attributed to the strong presence of leading pharmaceutical companies, rising cases of atopic dermatitis, and an advanced healthcare sector. The key players in the region are actively investing in the development of novel therapies and clinical trials as well as engaging in partnerships and collaborations, further ensuring the market's growth. The National Eczema Association estimates that roughly 10% of the population of the United States, approximately 31.6 million people have some form of eczema. Meanwhile, rising utilization of novel therapies and monoclonal antibodies, including Janus kinase (JAK) inhibitors, among both children and adults are supporting the evolution of treatment paradigms.

Additionally, the growing awareness among the patient population and healthcare professionals about the different treatment options available are further contributing towards the expansion of the market in North America. The region's dominance in the market is also supported by the increasing emphasis on research and development activities and the introduction of personalized medicines.

Meanwhile, the Asia-Pacific is expected to witness significant growth in the coming years due to the rapid population growth, increasing prevalence of atopic dermatitis, and rising investments in the healthcare sector by different countries.

Future Market Scenario (2025 - 2032F)

The global atopic dermatitis drugs market is poised for substantial growth in the coming years, supported by advancements in targeted therapies, increasing prevalence of atopic dermatitis across the globe, and the introduction of innovative biologics and small-molecule drugs. With ongoing research and development efforts, the market is expected to evolve significantly, offering more effective and long-term treatment options for managing the chronic inflammatory skin condition. Additionally, the advancements in biomarker research, proteomics, and genomics are supporting the gradual shift towards personalized treatments. Future therapies will be tailored on the basis of individual genetic profiles, severity of the disease, and treatment response. Moreover, the increasing adoption of digital health tools, artificial intelligence-powered apps, and wearable technologies are also expected to transform the management of the disease.

Key Players Landscape and Outlook

The key players of the market are increasingly engaging in novel product launches and receiving approvals from different regulatory bodies across the globe. For instance, in September 2024, Eli Lilly and Company received approval from the US FDA for EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor for treating adults and children with moderate-to-severe atopic dermatitis that cannot be controlled with the help of topical prescription therapies. This therapy is designed for patients whose condition is not well-controlled with topical treatments. EBGLYSS provides significant skin clearance as early as four weeks and meaningful itch relief within two weeks, with long-lasting efficacy through one year of treatment.

Leading pharmaceutical companies are also engaging in research and development activities. For instance, in August 2023, Lynk Pharmaceuticals Co., Ltd. announced positive results from its Phase II clinical trial LNK01001, for adult patients with atopic dermatitis. The preliminary data indicated that participants in both high-dose and low-dose groups demonstrated significant improvements in Eczema Area and Severity Index (EASI) scores in comparison with participants in the placebo group. Such efforts are expected to provide lucrative growth opportunities for the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Atopic Dermatitis Drugs Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drugs Class
    • 4.2.1.1. Corticosteroids
    • 4.2.1.2. Calcineurin Inhibitors
    • 4.2.1.3. PDE4 Inhibitors
    • 4.2.1.4. Biologics
    • 4.2.1.5. Others
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Topical
    • 4.2.2.2. Parenteral
    • 4.2.2.3. Oral
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Other Pharmacies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Drugs Class
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Atopic Dermatitis Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drugs Class
    • 5.2.1.1. Corticosteroids
    • 5.2.1.2. Calcineurin Inhibitors
    • 5.2.1.3. PDE4 Inhibitors
    • 5.2.1.4. Biologics
    • 5.2.1.5. Others
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Topical
    • 5.2.2.2. Parenteral
    • 5.2.2.3. Oral
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Other Pharmacies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Atopic Dermatitis Drugs Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Drugs Class
        • 5.3.1.2.1.1. Corticosteroids
        • 5.3.1.2.1.2. Calcineurin Inhibitors
        • 5.3.1.2.1.3. PDE4 Inhibitors
        • 5.3.1.2.1.4. Biologics
        • 5.3.1.2.1.5. Others
      • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.2.1. Topical
        • 5.3.1.2.2.2. Parenteral
        • 5.3.1.2.2.3. Oral
      • 5.3.1.2.3. By Distribution Channel
        • 5.3.1.2.3.1. Hospital Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Other Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Atopic Dermatitis Drugs Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Turkey
• 6.9. Poland

7. Asia-Pacific Atopic Dermatitis Drugs Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Atopic Dermatitis Drugs Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Atopic Dermatitis Drugs Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa

10. Global Epidemiology of Atopic Dermatitis

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Clinical Trial Overview

19. Competitive Landscape

• 19.1. Competition Matrix of Top 5 Market Leaders
• 19.2. SWOT Analysis for Top 5 Players
• 19.3. Key Players Landscape for Top 10 Market Players
  • 19.3.1. Pfizer Inc.
    • 19.3.1.1. Company Details
    • 19.3.1.2. Key Management Personnel
    • 19.3.1.3. Products and Services
    • 19.3.1.4. Financials (As Reported)
    • 19.3.1.5. Key Market Focus and Geographical Presence
    • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 19.3.2. Sanofi SA
  • 19.3.3. AbbVie Inc.
  • 19.3.4. Galderma Laboratories, L.P.
  • 19.3.5. Novartis AG
  • 19.3.6. Eli Lilly and Company
  • 19.3.7. Regeneron Pharmaceuticals Inc.
  • 19.3.8. LEO Pharma Inc.
  • 19.3.9. Otsuka Pharmaceutical Co., Ltd
  • 19.3.10. Incyte Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer